Months after pulling only drug from US, Oncopeptides takes back withdrawal request — but stays mum on why
What happens when you pull a request to pull your drug from the market?
Oncopeptides is trying to find out, revealing late Friday that it has contacted the FDA and rescinded a letter it sent back in October, requesting voluntary withdrawal of the NDA of its multiple myeloma drug, Pepaxto, in the US — the only place where it’s approved.
The Stockholm-based biotech triggered a major meltdown with the announcement back in October, as the withdrawal would force it to close its US and EU business units and enact significant layoffs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.